Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
20
21
22
23
24
26
27
28
29
30
31
1
12:00 AM - TEDMED 2017
2
3
4
5
Raleigh Health IT Summit
2017-10-19 - 2017-10-20    
All Day
About Health IT Summits Renowned leaders in U.S. and North American healthcare gather throughout the year to present important information and share insights at the Healthcare [...]
Connected Health Conference 2017
2017-10-25 - 2017-10-27    
All Day
The Connected Life Journey Shaping health and wellness for every generation. Top-rated content Valued perspectives from providers, payers, pharma and patients Unmatched networking with key [...]
TEDMED 2017
2017-11-01 - 2017-11-03    
All Day
A healthy society is everyone’s business. That’s why TEDMED speakers are thought leaders and accomplished individuals from every sector of society, both inside and outside [...]
AMIA 2017 Annual Symposium
2017-11-04 - 2017-11-08    
All Day
Call for Participation We invite you to contribute your best work for presentation at the AMIA Annual Symposium – the foremost symposium for the science [...]
Events on 2017-10-19
Raleigh Health IT Summit
19 Oct 17
Raleigh
Events on 2017-10-25
Events on 2017-11-01
TEDMED 2017
1 Nov 17
La Quinta
Events on 2017-11-04
AMIA 2017 Annual Symposium
4 Nov 17
WASHINGTON
Latest News Physicians and Health Practitioners

Global Analysis for Hospital Tumor Marker Market Trends & Forecast 2023

A new research report by Transparency Market Research (TMR), titled “Tumor Marker Testing Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” provides qualitative and quantitative insights into the market. The report offers a comprehensive overview of the factors impacting the growth of the market. It presents a detailed description of the competitive landscape of the global hospital tumor marker market.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4744

The growth of the global hospital tumor marker market can be primarily attributed to the increasing prevalence of cancer worldwide. Continuous advancements in technology are supporting easy identification of cancer, which is working in the favor of the market. Moreover, the increasing demand for efficient, cost effective, and safer treatments is boosting the adoption of hospital tumor marker. Another factor driving the market is the increasing government support for the development of advanced and efficient diagnosis and treatment tools for malignancy. Furthermore, anticipated technological breakthroughs in the field of multiple tumor market will create numerous growth opportunities for the market. However, the involvement of high cost in hospital tumor marker procedures is restraining the growth of the global market.

Different types of tumor markers are beta-2-microglobulin (B2M), alpha-fetoprotein (AFP), CA15-3, bladder tumor antigen (BTA), CA 125, CA27.29, calcitonin, CA 19-9, chromogranin A, carcinoembryonic antigen (CEA), inhibin, immunoglobulins, human chorionic gonadotropin (HCG), prostatic acid phosphatase (PAP), NMP22, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), prostate-specific antigen (PSA), and soluble mesothelin-related peptides (SMRP).

On the basis of geography, the global hospital tumor marker market is divided into Latin America, North America, Asia Pacific, Europe, and the Middle East and Africa. North America will continue to dominate the market until the end of 2023, followed by Europe. The dominance of this region can be attributed to the rising geriatric population and high awareness regarding tumor marker diagnosis. Moreover, various leading companies are domiciled in the region, thereby assuring easy penetration and healthy growth rate. The extensive support offered by government for the development of innovative and clinically advanced tools for cancer diagnosis. The rapidly growing population and the rising prevalence of cancer are fuelling the adoption of the global hospital tumor marker market.

The report profiles key players in the market along with their cost and revenue structure, latest developments, and business strategies. The leading players in the global hospital tumor marker market are F. Hoffmann-La Roche Ltd., Radient Pharmaceuticals Corporation, Mackay Life Sciences, Panacea Pharmaceuticals, Epigenomics AG, Targeted Diagnostics & Therapeutics, Siemens Healthcare, Bio-Rad Laboratories Inc., Biomedical Diagnostics, Becton, Dickinson and Company, Applied Genetic Technologies Corporation, and Abbott Laboratories.

Browse Full Research Report on Hospital Tumor Marker Market:
http://www.transparencymarketresearch.com/hospital-tumor-marker-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/